3 Undervalued Biotechnology & Medical Research Stocks for Monday, February 26
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Monday, February 26 based on AAII’s Stock Grades.Grace Malone
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.
Commentary & Analysis
7 Undervalued Biotechnology & Medical Research Stocks for Thursday, January 18
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Thursday, January 18 based on AAII’s Stock Grades.Jack Gilleland
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 28
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, March 28 based on AAII’s Stock Grades.Jenna Brashear
Why SenesTech Inc’s (SNES) Stock Is Up 12.35%
As of Monday, February 06, SenesTech Inc’s SNES share price has surged by 12.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
7 Undervalued Biotechnology & Medical Research Stocks for Wednesday, January 25
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Wednesday, January 25 based on AAII’s Stock Grades.Jack Gilleland
Financial Summary
| Share Statistics | SNES | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.9 | $618.0 | 4% |
|
| Shares Out (Mil) | 5.3 | 44.8 | 14% |
|
| Institutional Ownership | 99.1% | 85.3% | 85% |
|
| Float (Mil) | 4.1 | 47.4 | 10% |
|
| Beta | 0.26 | 0.70 | 16% |
|
| Avg Daily Volume (000s) | 38 | 390 | 25% |
|
| Price Change (52-week) |
(72.2%) | 68.6% | 8% |
|
| Growth | SNES | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.0% | 6.7% | 95% |
|
| Net Income (5yr) | 4.1% | (1.6%) | 46% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SNES | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $291 | 4% |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 32% |
|
| EPS (TTM) | ($1.364) | ($0.700) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $5 | 40% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 21% |
|
| Enterprise Value (Q1) (Mil) | $5 | $450 | 5% |
|
| Valuation | SNES | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.12 | 2.78 | 26% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SNES | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.2% | 67.0% | 78% |
|
| Net Margin | (294.7%) | (2.3%) | 3% |
|
| ROA | (70.7%) | (22.4%) | 8% |
|
| ROE | (107.4%) | (20.2%) | 8% |
|
| Liabilities to Assets | 35.8% | 32.2% | 27% |
|
| F-Score | 4 | 3 | 34% |
|
SenesTech, Inc. did not pass any screens on 8/20/2026.
